Mfg Part Number
Ab02328-10.3
Vector Labs Ab02328-10.3 Anti-CD23 [IDEC-152 (Lumiliximab, 6G5) ], Human IgG1, Fc Silent™, kappa (200 μg)
Quick Overview
The original chimeric antibody was generated from a monkey immunized with human CD23. Later on the chimeric version of the antibody was generated by cloning the variable regions of the antibody into human constant regions.
$517.40
Order will ship within 1-3 business days
| Product Class: | Purified |
|---|---|
| Clone ID: | IDEC-152 (Lumiliximab, 6G5) |
| Heavy Chain Modification: | Fc Silent™ |
| Synonyms: | Gomiliximab; FCER2; BLAST-2; FcεRII; Fc-epsilon-RII; Low affinity immunoglobulin epsilon Fc receptor; C-type lectin domain family 4 member J; Immunoglobulin E-binding factor; Lymphocyte IgE receptor |
| Amount: | 200 μg |
| Application Codes Clone: | FC, Therapeutic, IP |
| Shipping Temperature: | Wet Ice |
| Buffer Composition: | PBS with 0.02% Proclin 300. |
| Original Format: | IgG1 |
| Storage Temperature: | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C. |
| Chimeric Use Statement: | This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
| Specificity Statement: | This antibody is specific for human CD23. |
| Application Notes: | This antibody is also known as Gomiliximab. It binds CD23 or FCER2, a membrane protein and a "low affinity" receptor for IgE. It is also involved in IgE regulation and inflammation in allergic disorders, such as allergic rhinitis and allergic asthma. Phase I clinical trials in patients with allergic asthma revealed that IDEC-152 is safe and well-tolerated (PMID: 13679816). This antibody is also reported to have antitumor activity against chronic lymphocytic leukemia (CLL) in clinical trials (Woodworth et al., 2004; Byrd et al., 2004). Phase 1 study of Lumiliximab in patients with relapsed or refractory chronic lymphocytic leukemia reported that it was well tolerated and had clinical activity in patients. Flow cytometric analyses of blood samples were conducted to assess changes in lymphocyte subsets and to study both CD23 expression and binding of lumiliximab during the treatment (PMID: 17671129). This antibody also causes apoptosis in vitro and in vivo in CLL cells and drug-resistant lymphoma cells (Pathan et al., 2004; Zou et al., 2004). Lumiliximab was also found to inhibit allergen-induced responses in antigen-presenting cells and may be involved in modulating antigen-presenting cells and reducing T H 2-type immune responses (PMID: 16210051). This antibody was also used in the detection of human CD23 in the B cell-derived exosomes using immunoprecipitation (PMID: 20876574). |
| Brand | Vector Labs |
|---|---|
| UNSPSC | 12161500 |